DNA polymerase can be considered for use as a component in a diagnostic application if qualified by the end user, and does not carry the licensing restrictions, or costs, that Taq does
Invitrogen has introduced its Tfi DNA polymerase - a robust, cost-effective alternative to Taq.
PCR performance is comparable to Taq DNA polymerase in yield, specificity, fidelity, and robustness, says the company.
It can be substituted for Taq DNA polymerase in virtually any application and is ideal for genomic and cDNA targets less than 4kb.
It can be considered for use as a component in a diagnostic application if qualified by the end user.
In addition, Tfi does not carry the licensing restrictions, or costs, that Taq does.
